Shandong Tianming Pharmaceutical, a GMP-certified leader in advanced API and intermediate manufacturing, will unveil its latest innovations at CPHI China 2025 (June 24-26, Shanghai New International Expo Centre).
Visit us at Booth W2G30 to explore cutting-edge solutions reshaping pharmaceutical synthesis.
As an eight-time exhibitor with proven industry partnerships, we deliver more than products – we offer actionable pathways to:
1/Explore cutting-edge API synthesis technology and break through R&D bottlenecks
2/Unlock customized solutions:
3/Overcome Regulatory Hurdles
4/Global compliance escort, opening up international market access channels
– GLP-1 Agonist Intermediates: >99.9% chiral purity for obesity/diabetes pipelines
– Antibiotic Resistance Fighters: β-lactamase inhibitor scaffolds with 80% oral bioavailability
– On-Demand Synthesis: From R&D samples to commercial batches
With 300+ commercial APIs and 15 years of GMP excellence, Tianming enables partners across 40 countries to overcome synthesis scalability, compliance, and sustainability challenges.
We look forward to seeing you at CPHI China 2025!
Best regards
Sales Team
Shandong Tianming Pharmaceutical Group
The first commercial batch from a new intermediate supplier is not a formality. Here is the checklist, the five approval outcomes, and how to log the call.
A buyer-side decision tree for handling an intermediate supplier change notice — what to accept, contest, or reject, and how to log the call.
A supplier discontinuation is a deadline, not just bad news. The questions to ask in writing, the last-time-buy calculation, and the files to collect in time.
Manufacturer and supplier of pharmaceutical APIs and intermediates. Contact us for technical support and sourcing solutions.